MaaT Pharma: Advancing a pipeline of novel microbiome therapies across oncology
Onward Therapeutics: Characterizing the mechanism of action of a bispecific antibody in a pre-IND setting
High grade serous ovarian cancer ascites exhibit an impaired immune environment – immunosuppressive & protumoral – detrimental to the immune response
Background Malignant ovarian cancer ascites are increasingly recognized as major contributors to tumorigenesis and cancer progression. Ascites create a complex microenvironment where tumor cells interact with soluble mediators, metabolic factors, and immune cells. These interactions can influence tumor behavior, immune response, and treatment sensitivity. Characterizing the immune and metabolic composition of ovarian cancer ascites, together […]
Profiling of immune cell components and soluble factors in ovarian cancer ascites highlights impaired immune environment
Background Ovarian cancer ascites are increasingly recognized as important contributors to ovarian cancer progression. The behavior of tumor cells is strongly influenced by the composition of their surrounding microenvironment. Characterizing the cellular and soluble composition of ascites is therefore essential to better understand how this specific milieu affects tumor progression. In particular, ascites may contribute […]
Ovarian cancer ascites display altered immune environment featured by enhanced soluble factors and suppressive cellular context
Background The tumor microenvironment of epithelial ovarian cancer is unique among solid tumors, as tumor cells can shape their own microenvironment through the formation of malignant ascites. These ascites represent a complex mixture of soluble factors and cellular components. They are known to be enriched in macrophages, which have been suggested to acquire an M2-like […]
How fucoidan activates immune cells and independently stalls prostate cancer growth alongside Nivolumab
How CD95 keeps NF-κB switched off in triple-negative breast cancer — and what its loss unleashes
How CD95/Fas helps triple-negative breast cancer escape NK-cell control in preclinical models
Why IDO1 blockade lowered kynurenine but failed to improve anti-PDL1 efficacy in sarcoma
Why melanoma escapes BRAF inhibitors — the AhR transcription factor behind resistance and relapse
